An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray.
about
Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity.Multiple sclerosis symptoms and spasticity management: new data.What's new in multiple sclerosis spasticity research? Poster session highlights.The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
P2860
An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
An observational postmarketing ...... nabiximols) oromucosal spray.
@en
An observational postmarketing ...... nabiximols) oromucosal spray.
@nl
type
label
An observational postmarketing ...... nabiximols) oromucosal spray.
@en
An observational postmarketing ...... nabiximols) oromucosal spray.
@nl
prefLabel
An observational postmarketing ...... nabiximols) oromucosal spray.
@en
An observational postmarketing ...... nabiximols) oromucosal spray.
@nl
P2093
P2860
P356
P1476
An observational postmarketing ...... nabiximols) oromucosal spray.
@en
P2093
Adam Taylor
Brian Daka
Heather Lauder
Kari Karolia
Stephen Wright
Thomas Grint
Tilden Etges
P2860
P304
P356
10.2147/TCRM.S115014
P577
2016-11-11T00:00:00Z